For relapsing-remitting multiple sclerosis (RRMS), initial treatment with highly effective therapies yields better clinical outcomes at four years than a treatment-escalation approach, a study shows.

“Although escalation therapy is the most accepted treatment strategy for RRMS, it is not evidence based,” Dr Tim Spelman of Karolinska Institute, in Stockholm, and colleagues noted in JAMA Neurology.